ArticleAnnals of medicine2025
Exploring a potential novel marker for short-term mortality in decompensated cirrhosis: insights from a multicentre study.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe derived monocyte to lymphocyte ratio (dMLR) serves as an indicator of the overall systemic inflammatory and immune status. This study seeks to investigate the correlation between dMLR and 90-day mortality in patients diagnosed with decompensated liver cirrhosis (DLC).
methodsA total of 1,342 eligible patients from three medical centres were included in this study. Multivariable Firth-corrected logistic regression analysis was conducted to explore the independent association between dMLR and 90-day mortality. Additionally, restricted cubic spline (RCS) analysis was employed to examine the relationship between dMLR and mortality risk. These findings were subsequently validated in two independent cohorts. In the total cohort, the prognostic accuracy of dMLR for predicting outcomes in DLC patients was evaluated through receiver operating characteristic (ROC) curve analysis.
resultsIn the initial cohort, the observed 90-day mortality rate was 12.5%. ROC analysis showed that dMLR had comparable predictive ability to the Model for End-Stage Liver Disease. The multivariable Firth-corrected logistic regression analysis revealed that dMLR is an independent predictor of 90-day mortality. Furthermore, RCS analysis demonstrated that an increase in dMLR values corresponded with an elevated risk of mortality. These findings were corroborated in two validation cohorts.
conclusionsThe dMLR is independently associated with 90-day mortality in patients with DLC, with an increasing risk of death corresponding to higher dMLR values. dMLR may function as a simple, cost-effective, and reliable biomarker, assisting clinicians in identifying high-risk patients and may guide risk stratification and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.